Targeted therapeutic approaches for AML

Robert J. Arceci, Donald Small

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Acute myeloid leukemia comprises about 20% of the acute leukemias in children, but it is responsible for more than half of leukemic deaths due to leukemia. Compared to the tremendous success in the treatment of acute lymphocytic leukemia in the last three decades, resulting in more than 80% cure rate, improvements in AML therapy have been more limited with only about half of patients with AML being cured. Risk-adapted therapy has been the cornerstone of ALL therapy. One of the reasons for the success of this approach in ALL is that standard ALL induction and consolidation have been able to be intensified without causing significant morbidity and mortality. In contrast, the leukemic stem cell in most AML subtypes is inherently more drug resistant requiring significantly intensified courses of near myeloablative combinations of chemotherapeutic agents. This has resulted in a plateau in survival at approximately 50% along with significant morbidity and mortality.

Original languageEnglish (US)
Title of host publicationMolecularly Targeted Therapy for Childhood Cancer
PublisherSpringer New York
Pages59-82
Number of pages24
ISBN (Print)9780387690605
DOIs
StatePublished - 2010

Fingerprint

Stem cells
Consolidation
Pharmaceutical Preparations
Leukemia
Morbidity
Mortality
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Stem Cells
Survival

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Arceci, R. J., & Small, D. (2010). Targeted therapeutic approaches for AML. In Molecularly Targeted Therapy for Childhood Cancer (pp. 59-82). Springer New York. https://doi.org/10.1007/978-0-387-69062-9_4

Targeted therapeutic approaches for AML. / Arceci, Robert J.; Small, Donald.

Molecularly Targeted Therapy for Childhood Cancer. Springer New York, 2010. p. 59-82.

Research output: Chapter in Book/Report/Conference proceedingChapter

Arceci, RJ & Small, D 2010, Targeted therapeutic approaches for AML. in Molecularly Targeted Therapy for Childhood Cancer. Springer New York, pp. 59-82. https://doi.org/10.1007/978-0-387-69062-9_4
Arceci RJ, Small D. Targeted therapeutic approaches for AML. In Molecularly Targeted Therapy for Childhood Cancer. Springer New York. 2010. p. 59-82 https://doi.org/10.1007/978-0-387-69062-9_4
Arceci, Robert J. ; Small, Donald. / Targeted therapeutic approaches for AML. Molecularly Targeted Therapy for Childhood Cancer. Springer New York, 2010. pp. 59-82
@inbook{2a3c5d31bed44a83b148926e2213172a,
title = "Targeted therapeutic approaches for AML",
abstract = "Acute myeloid leukemia comprises about 20{\%} of the acute leukemias in children, but it is responsible for more than half of leukemic deaths due to leukemia. Compared to the tremendous success in the treatment of acute lymphocytic leukemia in the last three decades, resulting in more than 80{\%} cure rate, improvements in AML therapy have been more limited with only about half of patients with AML being cured. Risk-adapted therapy has been the cornerstone of ALL therapy. One of the reasons for the success of this approach in ALL is that standard ALL induction and consolidation have been able to be intensified without causing significant morbidity and mortality. In contrast, the leukemic stem cell in most AML subtypes is inherently more drug resistant requiring significantly intensified courses of near myeloablative combinations of chemotherapeutic agents. This has resulted in a plateau in survival at approximately 50{\%} along with significant morbidity and mortality.",
author = "Arceci, {Robert J.} and Donald Small",
year = "2010",
doi = "10.1007/978-0-387-69062-9_4",
language = "English (US)",
isbn = "9780387690605",
pages = "59--82",
booktitle = "Molecularly Targeted Therapy for Childhood Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Targeted therapeutic approaches for AML

AU - Arceci, Robert J.

AU - Small, Donald

PY - 2010

Y1 - 2010

N2 - Acute myeloid leukemia comprises about 20% of the acute leukemias in children, but it is responsible for more than half of leukemic deaths due to leukemia. Compared to the tremendous success in the treatment of acute lymphocytic leukemia in the last three decades, resulting in more than 80% cure rate, improvements in AML therapy have been more limited with only about half of patients with AML being cured. Risk-adapted therapy has been the cornerstone of ALL therapy. One of the reasons for the success of this approach in ALL is that standard ALL induction and consolidation have been able to be intensified without causing significant morbidity and mortality. In contrast, the leukemic stem cell in most AML subtypes is inherently more drug resistant requiring significantly intensified courses of near myeloablative combinations of chemotherapeutic agents. This has resulted in a plateau in survival at approximately 50% along with significant morbidity and mortality.

AB - Acute myeloid leukemia comprises about 20% of the acute leukemias in children, but it is responsible for more than half of leukemic deaths due to leukemia. Compared to the tremendous success in the treatment of acute lymphocytic leukemia in the last three decades, resulting in more than 80% cure rate, improvements in AML therapy have been more limited with only about half of patients with AML being cured. Risk-adapted therapy has been the cornerstone of ALL therapy. One of the reasons for the success of this approach in ALL is that standard ALL induction and consolidation have been able to be intensified without causing significant morbidity and mortality. In contrast, the leukemic stem cell in most AML subtypes is inherently more drug resistant requiring significantly intensified courses of near myeloablative combinations of chemotherapeutic agents. This has resulted in a plateau in survival at approximately 50% along with significant morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=84900250525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900250525&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-69062-9_4

DO - 10.1007/978-0-387-69062-9_4

M3 - Chapter

SN - 9780387690605

SP - 59

EP - 82

BT - Molecularly Targeted Therapy for Childhood Cancer

PB - Springer New York

ER -